retatrutide 2025 (Eli Lilly's triple GLP-1/GIP/Glucagon receptor agonist) just delivered the most impressive obesity + osteoarthritis data we've ever seen in the phase 3 TRIUMPH-4 trial: Retatrutide, Eli Lilly's Next-Gen Obesity

Indeed, there is a growing body of evidence suggesting a significant beneficial class effect associated with SGLT2 inhibition, resulting in MACE, cardiovascular death and hospitalization for heart failure (HHF) reduction, despite some variabilities in the findings provided by individual CVOTs (40)

All treated participants were able to shed at least 5% of their weight by 24 weeks, while 45% dropped 20% of their body weight at this time point

You're Missing Doses or Not Taking the Medication Consistently Consistency matters

32 While many hand sanitizer warning letters were issued following detention and testing at the U.S